News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abiomed Inc
(NQ:
ABMD
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 21, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abiomed Inc
< Previous
1
2
3
4
5
Next >
What 4 Analyst Ratings Have To Say About Abiomed
April 06, 2022
Abiomed (NASDAQ:ABMD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Recap: Abiomed Q3 Earnings
February 03, 2022
Abiomed (NASDAQ:ABMD) reported its Q3 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 3, 2022
February 03, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter.
Via
Benzinga
First Patient in Japan Treated with Impella 5.5 with SmartAssist
April 06, 2022
From
Abiomed, Inc.
Via
Business Wire
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
April 05, 2022
With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks.
Via
InvestorPlace
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
March 21, 2022
From
Abiomed, Inc.
Via
Business Wire
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 08, 2022
From
Abiomed, Inc.
Via
Business Wire
Abiomed's Return On Capital Employed Insights
February 04, 2022
According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million.
Via
Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
February 03, 2022
From
Abiomed, Inc.
Via
Business Wire
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
Ominous Death Cross Forms On Abiomed's Chart
January 25, 2022
If history is any guide, there may be trouble ahead for shares of Abiomed (NASDAQ:ABMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 20, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
January 14, 2022
From
Abiomed, Inc.
Via
Business Wire
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
January 12, 2022
From
Abiomed, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
January 10, 2022
Gainers Inari Medical (NASDAQ:NARI) stock...
Via
Benzinga
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
January 10, 2022
From
Abiomed, Inc.
Via
Business Wire
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 29, 2021
From
Abiomed, Inc.
Via
Business Wire
Abiomed to Present at Upcoming Investor Conferences
November 18, 2021
From
Abiomed, Inc.
Via
Business Wire
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
November 04, 2021
From
Abiomed, Inc.
Via
Business Wire
Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines
November 03, 2021
From
Abiomed, Inc.
Via
Business Wire
TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
November 01, 2021
From
Abiomed, Inc.
Via
Business Wire
ABIOMED, inc (ABMD) Q2 2022 Earnings Call Transcript
October 28, 2021
ABMD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
October 28, 2021
From
Abiomed, Inc.
Via
Business Wire
Abiomed's Earnings Outlook
October 27, 2021
Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
October 07, 2021
From
Abiomed, Inc.
Via
Business Wire
Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag
August 18, 2021
The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the...
Via
Benzinga
Exposures
Product Safety
FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump
August 18, 2021
From
Abiomed
Via
Business Wire
ABIOMED, inc (ABMD) Q1 2022 Earnings Call Transcript
August 05, 2021
ABMD earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.